News Center - FAIS Africa

Latest News

Register now for the 12th African Congress of Immunology (FAIS 2024)
9.2.24
21st Biennial Meeting of the European Society for Immunodeficiencies (ESID 2024)
7.25.24
IES Webinar: Clinical Aspects of Eosinophilia
7.19.24
Discover the Inaugural Issue of Vaccines Beat!
7.19.24
The Quarterly IUIS Newsletter is out!
7.5.24
FASCanto II available for Donation!
7.5.24
1st Annual Meeting of the International Society of Nucleic Acid Immunity (NAIS)
7.5.24
IUIS-FAIS-SAIS IMMUNO-SOUTH AFRICA
6.21.24
Society for Leukocyte Biology (SBL) – 1 Month Until the Abstract and Award Submission Deadline!
6.20.24
Post-doctoral Research Associate – Faculty of Health Division of Clinical Medicine
6.10.24
APPLICATION TO THIS YEAR’S SCIENCE & SCILIFELAB PRIZE IS OPEN!
6.7.24
Post of Senior Lecturer – University of the Witwatersrand, Johannesburg, South Africa
6.7.24
Webinar hosted by the International Eosinophil Society “Eosinophilic Granulomatosis with Polyangiitis (EGPA)” Wednesday, 19 June 2024
5.23.24
Call for Abstract Extended Deadline for Cytokines 2024 / KAI 2024 – May 30, 2024 (23:59 KST)!
5.23.24
Host An In-Person IUIS Immunology Course in 2025
5.4.24
The Moroccan Society of Immunology (SMI) celebrates the International Day of Immunology 2024
5.2.24
Benin Immunology Society (BIS) – Day of Immunology Event
4.22.24
Webinar – Tanzanian Immunology Society & Kenya Society for Immunology
4.18.24
Société Tunisienne d’Immunologie (STI) celebrates the Day Of Immunology
4.15.24
The Nigerian Society for Immunology (NSI) – Event for Day of Immunology 2024
4.12.24
The 2024 Michelson Prizes: Next Generation Grants
4.8.24
Africa CDC/ Africa PGI Webinar Series on Pathogen Genomic Surveillance in Africa
4.8.24
FAIS Newsletter March 2024
3.27.24
Day of Immunology 2024
3.19.24
4th AIDS-related Mycoses Workshop
2.23.24
MoBility for Research and African Integration through Health Sciences – Information Session
2.19.24
17th International Symposium on Dendritic Cells (DC2024Barcelona)
2.7.24
African Nutrition Leadership Programme (ANLP) – Support Program for PhD Students
1.25.24
Federation of Clinical Immunology Societies (FOCIS) 2024 Annual Meeting
1.8.24
12th African Congress of Immunology (FAIS 2024)
12.28.23
MSc in Integrated Immunology (Part-time, Distance Learning)
11.17.23
Calling for Nominations to the IUIS Education Committee and its online subcommittee.
11.9.23
ACTERIA Doctoral Thesis Prizes awarded by EFIS in immunology and allergology
10.6.23
IUIS Survey – How do we define “Clinical Immunology” around the globe?
10.5.23
Applications Open for Two Scholarships – Spring School on Immunology of the DGfI
8.23.23
2024 IAPIDS Advanced Clinical Immunology Training and Career Building Course
8.23.23
Biophysics in Africa Colloquium – Monthly Colloquium series
8.3.23
The call for applications for the EJI Ita Askonas Prize awarded by EFIS is open!
7.18.23
ASML 2023 – African Society for Laboratory Medicine – Abstract Submission Deadline Extended to 7 August!
6.23.23
Post-Webinar Report on “The Role of Immunologists in Shaping Public Health Strategies” – Hosted by the Benin Immunology society a member society of the Federation of African Immunology Societies (FAIS)
6.22.23
Wellcome Discovery Research Webinars for Global Researchers
6.5.23
PROBio-Africa Fellowships
5.5.23
A Benin Society of Immunology Event – FAIS Celebration of the Day of Immunology 2023!
4.24.23
IUIS Newsletter – March 2023
3.31.23
IMMUNO-ZAMBIA Workshop Report
3.28.23
IUIS 2023 – Only One Week Left to Submit an Abstract!
3.13.23
Africa CDC/ Africa PGI Webinar Series on Pathogen Genomic Surveillance in Africa
2.28.23
IUIS-SMI-FAIS IMMUNO-MOROCCO 2023 Course
2.17.23
WHIP Immunoparasitology Meeting
2.13.23
International Primary Immunodeﬁciencies Congress (IPIC2023)
2.2.23
IUIS/AAI Awards Summer Courses in Immunology
1.30.23
Mastercard Foundation AfOx Scholarships
1.12.23
WHIP 2023 Virtual Seminar Series
1.12.23
2023 International Day of Immunology
12.19.22
18th IUIS International Congress of Immunology – Cape Town, South Africa – 27 November to 2 December 2023
10.3.22
IUIS-FAIS-SANTHE-ISZ Immuno-Zambia 2022: Advanced Immunology of the “BIG FOUR” (COVID-19, HIV, TB and Malaria) infectious diseases”
8.15.22
IUIS-BIS joint workshop on flow cytometry: From basic principles to research applications
7.15.22
Cytokines 2022 Hybrid Joint Meeting with ILC4, 20-23 September in Hawaii
6.23.22
26th Annual Jonathan Lax Award Lecture
6.14.22
Call For Nominations – IUIS Elections 2022-2025
5.18.22
A new TB vaccine – is it cost-effective and efficient?
2.18.22
More SARS-CoV-2 variants?
2.16.22
HIV vaccine progress
2.11.22
A nanoparticle based vaccine for SARS-CoV-2 neutralization and protection
2.8.22
Predicting transplant rejection using proteoforms
2.7.22
Epstein-Barr Virus found to trigger Multiple Sclerosis
2.2.22
Treatment with interferon-λ confers protection from SARS-CoV-2 variants – Beta and Omicron
2.2.22
Th17 and Multiple Sclerosis (MS)
1.31.22
Passing of Professor Reinhold Schmidt – EFIS
1.28.22
Why is Omicron less severe than Delta?
1.25.22
A new target for TB treatment with great potential
1.25.22
Formation of tertiary lymphoid tissue: fighting chronic inflammation
1.25.22
Our natural defence to skin cancer – new insights
1.18.22
Can we use cannabinoids to block SARS-CoV-2 viral entry?
1.18.22
Toothpaste – a trigger for gut inflammation
1.12.22
How do immune cells invade tissue?
1.12.22
T-cell response to Omicron – conferred immunity
1.12.22
B cell lymphomas and the role of TET enzymes
1.3.22
Changes in SARS-CoV-2 Omicron variant spike protein
1.3.22
Resistance to key antimalarial drug?
1.3.22
COVID-19 and idiopathic pulmonary fibrosis (IPF)
1.3.22
Can fat help us combat infection?
1.3.22
Antibody profile in response to SARS-CoV-2 – serological profile and specificity of maternal and neonatal cord blood
12.14.21
Germline mutations in innate immunity associated with the risk for breast cancer: case of C-reactive protein
12.8.21
New Insights into the diagnosis, prognosis and monitoring of Multiple Myeloma: What’s the role of the Heavy/Light Chain Assay?
12.2.21
Antiretroviral therapy influences tumour development in patients with HIV
12.2.21
Promotion of protective anti-tumour CD8+ T cell immunity – a new treatment for tumours
11.26.21
Alzheimer’s Disease – a potential vaccine?
11.24.21
Immune system evasion – the HIV-infected cell
11.22.21
Improving existing malaria vaccines – new insights
11.17.21
Detection of autoantibodies in patients with multisystem inflammatory syndrome in children (MIS-C)
11.15.21
Immunotherapy – new insights into how CD8+ T cells become unresponsive to treatment
11.11.21
Toxoplasma gondii-Induced Neutrophil Extracellular Traps Activate Neutrophils and promote T cell recruitment
11.11.21
Predicting response to immunotherapy in patients with clear cell renal cell carcinoma (ccRCC)
11.5.21
Pregnancy and its influence on the immune response to SARS-CoV-2
11.5.21
Neutrophils as potential early indicators of tuberculosis severity
11.5.21
Microbial fitness and IgA – a balancing act for the intestinal flora
11.5.21
Malaria Vaccine Breakthrough: Shaking or Stirring the Field?
10.20.21
A novel immunogene CD47-targeting therapy inhibiting tumour growth
10.14.21
A novel inhibitor of dengue virus
10.12.21
Variations in leukocytes – three months following mild COVID-19 infection
10.12.21
Insights into the development of the blood and immune systems in prenatal bone marrow
10.6.21
New hope – a potential new treatment for sepsis
10.1.21
Identification of D6R and C5aR2 as key molecules with the potential to combat inflammatory diseases
9.30.21
Microglial cells – immune cells of the CNS breaking down harmful proteins in the brain
9.27.21
A new cell type contributing to inflammatory skin diseases
9.22.21
How does vitamin A enter our intestinal immune cells and what are the implications?
9.20.21
Neutrophilic aid – extracellular traps to enhance macrophage directed bacterial killing
9.20.21
A new tool for predicting COVID-19 severity and prognosis
9.20.21
Ad26.CoV2.S vaccine significantly boosts pre-existing SARS-CoV-2 specific antibodies but not CD4 T cell immune responses
9.9.21
A potential new biomarker for Preeclampsia
9.6.21
Reprogramming the Tumour Microenvironment – Improving Cancer Survival
9.1.21
Does B.1.351 SARS-CoV-2 variant escape T cell immune responses?
8.27.21
Neutrophil dominance leads to protection from P. falciparum blood-stage merozoites
8.20.21
A novel pathway of immune and host cell evasion by Mycobacterium tuberculosis
8.19.21
Pre-clinical evaluation of a vaccine that induces both SARS-Cov-2 and yellow fever virus immunity
8.19.21
Can neutrophils adopt antigen-presenting cell functions, and if so how?
8.13.21
IUIS Webinar: HIV prevention- antibodies and vaccine development (part 2)
8.10.21
IUIS Webinar: HIV prevention- antibodies and vaccine development (part 1)
8.10.21
Potent neutralising antibodies against SARS-CoV-2 variants of concern
8.2.21
World Hepatitis Day: proof of concept HCV nanoparticle vaccine
8.2.21
Immunogenicity of heterologous SARS-CoV-2 vector vaccine prime-mRNA vaccine boost vaccination strategy
8.2.21
Global Immunotalks Highlight: Immune responses after dengue virus infection: friend or foe?
7.22.21
What does HLA-DR expression on CD4 T cells indicate?
7.19.21
IUIS-Immunopaedia-Frontiers Webinar: Immunopathology of COVID 19 lessons from pregnancy and from ageing
7.14.21
Could infection with other viruses provide protection from SARS-CoV-2?
7.13.21
10th IDA Symposium
7.8.21
Webinar: HIV prevention: antibodies and vaccine development
7.8.21
Microbes prime foetal immune cells during early human development
7.8.21
The role of emergent food allergies in rethinking vaccine strategies
7.8.21
How Sickle-trait hemoglobin protects against severe Plasmodium falciparum malaria
7.8.21
HIV-1 and TB coinfection skews the SARS-CoV-2 T cell response
7.1.21
Webinar: Immunopathology of COVID-19: lessons from pregnancy and from ageing
6.29.21
WNT7A: The new marker for resting T cells
6.29.21
Does serial administration of HIV-specific VRC01 bnAbs prevent HIV acquisition?
6.28.21
An update on the Shock and kill HIV cure strategy
6.24.21
IUIS-Immunopaedia-Frontiers Webinar: Clinical representation of hyperinflammation
6.22.21
Abstract Deadline Extended – 11th African Congress of Immunology
6.18.21
IUIS-Immunopaedia-Frontiers webinar: In-depth characterisation of immune cells in Ebola virus
6.17.21
BCG reduces all-cause infectious diseases in the first 6 weeks of life in infants!
6.15.21
IUIS-Immunopaedia-Frontiers webinar: Getting to the “bottom” of arthritis
6.10.21
Webinar: Mapping human immune responses to Ebola virus infection provides insight into viral pathogenesis
5.31.21
11th African Congress of Immunology – FAIS 2021
5.17.21
Exploring characteristics of COVID-19 to guide public health policies & therapeutic interventions
5.11.21
C5a-C5aR1 axis plays a role in cobra venom immunopathology
5.7.21
Webinar: SARS-COV-2 Vaccines: Opportunities & Challenges for Africa
5.5.21
Antibody response to vaccination post-COVID-19 infection
5.4.21
Aged Neutrophils support tumor metastasis
4.29.21
P.falciparum secretes extracellular vesicles with functional 20S proteasomes to prime RBCs for parasite invasion
4.28.21
Pregnant women show elevated levels of anti-inflammatory glycosylation patterns of IgG antibodies
4.28.21
Webinar: Regulatory B cells and gut-microbiota: an intricate acting balance in autoimmunity
4.22.21
First report on Effectiveness of HPV Vaccination in LMICs – Rwanda and Bhutan
4.20.21
Does ACE2 expression & cytotoxic lymphocyte levels indicate a risk factor for COVID-19?
4.16.21
Immunopathogenesis of Autoimmune Hepatitis
4.14.21
Webinar: Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
4.12.21
B1.1.135 (501Y.V2) induces cross-reactive Ab responses to other SARS-CoV-2 variants
4.9.21
IUIS-Immunopaedia-Frontiers Webinar on Immunology taught by P. falciparum
4.8.21
Is tumour circulating DNA a better tool for cancer diagnostic and prognostic than immunological biomarkers?
4.1.21
HPV & HIV infection are associated with high levels of activated CD4 T cells in the cervix uteri
3.30.21
Predicting tissue graft outcomes using immune markers
3.29.21
Flynn Webinar: Immune features associated natural infection
3.16.21
BCG vaccination reduces infection in the elderly
3.15.21
Exploratory study investigates the relationship between recent vaccinations and SARS-CoV-2 infection rates
3.12.21
Immunology taught by Plasmodium falciparum
3.10.21
Statins: improved survival rates and reduced mortality rate in COVID-19 patients
3.10.21
Myeloid-derived suppressor cells: drivers of severe COVID-19 disease?
3.8.21
The path to sterilizing immunity against tuberculosis
3.3.21
IUIS Webinar on harnessing innate immunity from cancer therapy to COVID-19
3.3.21
Uterine NK cell differentiation during the menstrual cycle and pregnancy
2.26.21
Global ImmunoTalk on dissecting the interaction of parasites with the immune system
2.24.21
Researchers may have found a way to “cure” cat allergies?
2.22.21
The antibody response to SARS-CoV-2 501Y.v2 variant and vaccine implications
2.19.21
Do mutations in SARS-CoV-2 variants reduce the functional activity of mRNA-vaccine elicited Abs?
2.17.21
IUIS/Immunopaedia-Frontiers Webinar on Immunoregulation and the tumor microenvironment
2.15.21
Webinar: Harnessing innate immunity in cancer therapy and beyond
2.15.21
Are current putative COVID-19 vaccines effective against the B.1.351 variants?
2.9.21
Phase 2a trial provides evidence for potential pancreatic cancer immunotherapy
2.8.21
COVID-19 is associated with increased MAIT cell activation and cytotoxicity
2.3.21
Webinar: Immunoregulation and the tumor microenvironment
2.2.21
Saliva viral load could be a potential correlate of severe COVID-19
2.2.21
Mutations in SARS-Cov-2 B.1.351 variant reduces vaccine induced Ab neutralisation
1.28.21
Immuno-metabolism and cognitive decline
1.25.21
Ad26.COV2.S is safe and immunogenic
1.22.21
SARS-CoV-2-specific Memory B cells persist up to 8 months post infection
1.19.21
Gene editing as a potential sickle cell disease immunotherapy
1.19.21
Not all SARS-CoV-2 mutations lead to reduced antibody neutralisation capacity
1.13.21
Development of a serological diagnostic of Johne’s Disease
1.12.21
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
1.6.21
Lack of interference by type I interferons leads to severe COVID-19
12.17.20
BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccine efficacy results
12.14.20
Potential vitiligo immuno-therapeutic: antigen-specific CAR-Tregs
12.10.20
Vaccine elicitation of engineered HIV-specific B cells: inducing bnAbs
12.8.20
Which COVID-19 vaccine will be the most effective?
12.7.20
SARS-CoV-2 serological assay on-a-chip
12.3.20
How does SARS-CoV-2 evade the immune defences?
11.30.20
Investigating Ebola immunity using single cell technologies
11.27.20
Investigating the role of surfactants during TB using the lung-on-a-chip model
11.26.20
Gut Inflammation Linked to a Debilitating Skin Condition
11.24.20
Safety and immunogenicity of Sputnik V vaccine
11.23.20
SARS-CoV-2 mRNA-1273 vaccine shows signs of potential efficacy
11.19.20
Pfizer and BioNTech COVID-19 vaccine
11.17.20
The role of Galectin-3 in the tumor microenvironment
11.16.20
Frontiers Research Topic – Immune-Related Non-Communicable Diseases in Africa
11.13.20
Developing an oral polio vaccine that does not cause vaccine-associated polio
11.9.20
Meningeal-IgA+ plasma cells contribute to CNS-immunity
11.6.20
Should we consider aerosol vaccines for COVID-19
11.4.20
Testing potential neonatal sepsis drugs using a murine neonatal sepsis
11.4.20
Granuloma formation during S.mansoni infection: protective or pathogenic?
11.4.20
SAIS/Immunopaedia COVID-19 Webinar on COVID-19 Cytokine Storm & Paediatric COVID-19
10.28.20
Impact of intermediate hyperglycaemia and diabetes on immune dysfunction in TB
10.26.20
NIH COVID-19 lecture on SARS-CoV-2 mRNA vaccine
10.21.20
Auto-antibody responses to type I IFNs is a clue to severe COVID-19
10.20.20
Do lipid bodies play a role in innate immunity?
10.19.20
Trained Immunity in Dogs
10.16.20
NIH COVID-19 lecture on SARS-CoV-2 neutralising antibodies
10.14.20
Why is flu vaccine induced immunity short-lived?
10.12.20
Molecular mimicry: perfect match propels pathologies
10.9.20
SAIS/Immunopaedia Webinar: Immunothrombosis & COVID-19
10.7.20
Safety and immunogenicity of the SARS-CoV-2 mRNA-1273 vaccine candidate in older age
10.6.20
Genetically modified Lactococcus lactis- A potential microbial therapeutic for acute colitis?
10.5.20
IUIS Webinar: Impairment of the immunological and neurological synapses by respiratory viruses
10.2.20
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate
9.29.20
Why do people with the Dantu blood group have a lower risk of developing malaria?
9.28.20
Boosting of antibody responses against the V2 and V3 region of the HIV-1 Env
9.28.20
SAIS/Immunopaedia COVID-19 Webinar on Severe vs mild COVID-19 immunity, and intersection between Nicotinamide pathway & COVID-19
9.25.20
A mechanism for severe COVID-19 in patients with obesity and diabetes?
9.22.20
HIV Viral reservoir: quality rather quantity matters
9.21.20
IUIS Webinar: Tracking SARS-CoV-2 in Ghana
9.16.20
Inclusion of non-spike proteins in SARS-CoV-2 vaccines may be important for the induction of protective T cell memory
9.15.20
CD229 CAR: New therapy for multiple myeloma
9.14.20
Immuno-Algeria: Drug hypersensitivity in TB/HIV endemic settings
9.11.20
SAIS/Immunopaedia Webinar on BCG & COVID-19
9.9.20
Male and female immune responses to SARS-CoV-2 substantially differ
9.9.20
How the Regulator is Regulated: Insight into immune-related Protein holds therapeutic value
9.7.20
Are Lung microbial products driving hyperinflammation in severe COVID-19?
9.3.20
IUIS Webinar: COVID-19 & Immune Compromise
9.2.20
SARS–CoV-2 infection of the placenta
8.31.20
Immuno-Algeria: Microbial dysfunction & allergy
8.28.20
Can saliva be used to test for antibodies to SARS-CoV-2?
8.27.20
SAIS/Immunopaedia Webinar: COVID-19 Vaccines
8.26.20
COVID-19 & Multisystem inflammatory syndrome in children
8.25.20
Do SARS-CoV-2-specific T cells confer long-lived protection?
8.24.20
Immuno-Algeria: Allergic activity of IgE binding molecules
8.21.20
Convalescent plasma therapy for COVID-19 is safe
8.20.20
IUIS Webinar: Stress dampens anti-viral immunity
8.19.20
COVID-19 in vitro studies: Use the right cell line
8.18.20
Immuno-Algeria: IgE & its receptors as a pharmacological targets
8.14.20
SARS-CoV-2 monoclonal antibodies as potential COVID-19 treatment
8.13.20
IUIS Webinar: Predicting survival and severity of COVID-19
8.12.20
Treating COVID-19 with IgG, should we be cautious?
8.11.20
RNA-based vaccine BNT162b1 induces robust IgG and T cell immunity
8.11.20
SAIS COVID-19 Webinar Series 18 Aug
8.6.20
IUIS Webinar: Longitudinal COVID-19 Immune Profiling
8.6.20
Immuno-Algeria 2020: Cellular components of the allergic response
8.6.20
Tissue tolerance in COVID-19
8.4.20
Does the D614G mutation in SARS-CoV-2 spike protein result in the virus being more susceptible to neutralization by the host?
8.3.20
SAIS COVID-19 Webinar Series 4 Aug
8.3.20
IUIS Webinar: Utilising Ramos B cell engineering to measure SARS-CoV-2 Ab responses
7.24.20
Critically ill COVID-19 patients show evidence for extrafollicular B cell activation
7.23.20
Immuno-Ethiopia: Xenodiagnosis of Leishmaniasis
7.22.20
ChAdOx1 nCoV-19 vaccine is safe and immunogenic
7.21.20
Targeting COVID-19 immunopathology using rapamycin
7.20.20
Development of a potent SARS-CoV-2 nAb using llamas
7.17.20
mRNA Vaccine against SARS-CoV-2 induces robust Ab responses
7.16.20
IUIS Webinar: Seeking correlates of COVID-19 protection and pathology
7.15.20
Immuno-Ethiopia: Anti-leishmania Immunity
7.14.20
COVID-19 & GIT symptoms
7.13.20
IUIS Webinar: COVID-19 Monoclonal Abs
7.10.20
Aging & COVID-19
7.9.20
Immuno-Ethiopia: Sand flies & Leishmaniasis
7.8.20
Innate T cells & severe COVID-19
7.7.20
Multi-organ damage is a hallmark of severe COVID-19
7.6.20
IUIS Webinar: COVID-19 in South Africa
7.3.20
Are polymorphisms in the ACE2 locus important for COVID-19 severity?
7.2.20
Immuno-Ethiopia: Genetics of Fungal Immunology
7.1.20
Do mutations in the SARS-CoV-2 spike protein enhances viral infectivity?
6.30.20
Will the COVID-19 pandemic result in significant neuropsychiatric sequelae?
6.29.20
IUIS Webinar: Involvement of C5a-C5aR1 axis in COVID-19 pathology
6.29.20
How effective is Dexamethasone for the treatment of patients with COVID-19?
6.29.20
SARS-CoV-2-specific IgG and IgM in asymptomatic individuals wane quickly
6.29.20
Does breast milk contain SARS-CoV-2?
6.29.20
Are blood groups associated with severe COVID-19 respiratory failure?
6.22.20
Development of an inactivated vaccine candidate for SARS-CoV-2
6.19.20
IUIS Webinar: Understanding Infection and Immunity of SARS-CoV-2
6.18.20
IUIS Webinar: Respiratory Immunity and COVID-19
6.17.20
Identification of two B cell epitopes that induce neutralising Ab in COVID-19 patients
6.16.20
COVID-19 vaccines: can alum based adjuvants improve induction of nAbs?
6.15.20
What evidence is there for pre-existing antibody responses to SARS-CoV-2?
6.12.20
Is COVID-19 an endothelial disease?
6.11.20
A recombinant adenovirus type-5 vectored COVID-19 vaccine appears safe and immunogenic in a first-in-human trial
6.10.20
SARS-CoV-2 monkey model shows protection from re-infection
6.9.20
An exuberant inflammatory host response to SARS-CoV-2 leads to COVID-19
6.8.20
IUIS Webinar: Role of cellular responses in COVID-19
6.5.20
SARS-CoV-2 infection in young children and Kawasaki-like disease
6.4.20
No evidence that BCG vaccination can protect against SARS-CoV-2 infection
6.3.20
Do we have more T cell immunity to SARS-CoV-2 than we think?
6.2.20
Is the rapid generation of neutralizing antibodies to SARS-CoV-2 good news for preventing reinfection?
6.1.20
The current status of COVID-19 immunology
5.29.20
IUIS Webinar: Trained immunity and BCG vaccination: a tool against COVID-19?
5.28.20
A nail in the coffin of (hydro)chloroquine treatment against COVID-19?
5.27.20
SARS-CoV-2 found in semen
5.26.20
Can anti-HIV drugs, Lopinavir and Ritonavir, be used to treat patients with severe COVID-19?
5.26.20
Can the Cytokine Release Syndrome in COVID-19 patients be treated using CCR5 blocking antibody therapy?
5.22.20
IUIS Webinar: Adaptive Immunity in COVID-19
5.21.20
Can a Chimpanzee vector vaccine prevent SARS-CoV-2 pneumonia?
5.20.20
Getting to the guts of SARS-CoV-2 infection
5.19.20
Cigarette smoke triggers increased ACE-2 expression in the lung
5.18.20
Respiratory disease and viral shedding in rhesus macaques inoculated with SARS-CoV-2
5.15.20
IUIS Webinar: What cancer immunologists are doing about COVID-19?
5.14.20
BCG induced trained immunity & COVID-19
5.13.20
Is there a SARS-CoV-2 receptor (ACE2) expression difference between males and females?
5.12.20
Roles of different anti-SARS-CoV-2 antibodies in COVID-19 disease and protection
5.12.20
Opinion: Exaggerated immune response to COVID-19
5.11.20
Can neonates born to mothers with COVID-19 acquire maternal infection?
5.8.20
Mutation in the Spike protein may explain higher infectivity of SARS-CoV-2 and accelerated disease
5.7.20
IUIS Webinar: Global outbreaks – Interferons as 1st responders
5.6.20
An inventory of the vaccine candidates to SARS-CoV-2
5.5.20
COVID-19: extending or relaxing distancing control measures
5.4.20
Is a self-amplifying RNA SARS-CoV-2 lipid nanoparticle a good vaccine candidate?
5.3.20
SARS-CoV-2 transmission exploits existing secretory pathways in the nasal cavity: a vaccine/drug target?
5.2.20
The role of complement in COVID-19 pathogenesis
5.1.20
Scientific Response to COVID-19 Video
4.30.20
Can two FDA-approved drugs be re-purposed to clear SARS-CoV-2 infection?
4.29.20
Should we consider SARS-CoV-2 human challenge models for vaccine testing?
4.28.20
Mask wearing to reduce the spread of COVID-19
4.27.20
Development of inactivated SARS-CoV-2 vaccines
4.26.20
Cytokine Release Syndrome & COVID-19
4.25.20
COVID-19 Antibody Immunology Video
4.24.20
Uncertainty is hampering doctors’ ability to treat COVID-19
4.23.20
Detection of SARS-CoV-2 nAbs in cats
4.22.20
Susceptibility of domestic animals to SARS-Cov-2
4.21.20
Opinion: Indian population could have intrinsic immunity to resist COVID-19 challenge
4.20.20
Viral dynamics in mild vs severe COVID-19
4.19.20
SARS-CoV-2 transmission and mask wearing
4.18.20
Convalescent sera option for containing COVID-19
4.17.20
Webinar: Rino Rappuoli on COVID-19 Vaccines – 6th April
4.6.20
COVID-19 and SARS-CoV-2
3.25.20
FAIS Legacy Report – Selassie Kumordjie
2.21.20
Immuno-Algeria 2020
1.20.20
FAIS Legacy Project – Esemu Livo Forgu Report
1.8.20
FAIS at the 17th International Congress of Immunology
11.13.19
FAIS President and Secretary General in Innovations in Immunology
11.13.19
FAIS in Beijing
10.18.19
FAIS Legacy Project – Student Feedback
10.12.19
The Mawazo Institute’s PhD Scholars Programme
10.6.19
FAIS President Honoured
9.18.19
The FAIS Legacy Project in Nature
8.2.19